Modernes Asthma-Management

Die Ziele einer modernen Asthma-Therapie sind die Symptomprävention und die Asthma-Remission. Die diagnostische Voraussetzung hierfür ist die Phänotypisierung der Patienten. Dieser Beitrag stellt die 3 darauf basierenden Säulen des modernen Asthma-Managements vor: Basismaßnahmen (wie Schulung und Vermeidung von Asthma-Triggern), die Therapie mit DMAADs („disease-modifying anti-asthmatic drugs“) und die Behandlung von Komorbiditäten.

Abstract

Symptom prevention and remission are the goals of asthma treatment. Precise phenotyping of the patients, including history, lung function, allergology and measurement of type 2 biomarkers, is the essential prerequisite for treatment success. Basic measures, treatment with DMAADs („disease-modifying anti-asthmatic drugs“: predominantly inhaled corticosteroids, biologics, and allergen immunotherapy) and treatment of comorbidities are the cornerstones of modern asthma management. The treatment of upper airway diseases such as allergic rhinitis (often associated with early-onset asthma) or chronic rhinosinusitis (often associated with adult-onset asthma, with 2 forms: either with nasal polyps, CRSwNP, or without nasal polyps, CRSsNP) is of major importance in this regard.

Kernaussagen

• Ziel einer modernen Asthma-Therapie ist die Symptomprävention und das Erreichen einer Asthma-Remission.

• Die genaue Patienten-Phänotypisierung (Anamnese-Erhebung, Lungenfunktionsprüfung, allergologische Diagnostik, Biomarker-Messung) ist Voraussetzung für den Therapieerfolg.

• Das moderne Asthma-Management besteht aus Basismaßnahmen, der Therapie mit DMAADs – v.a. inhalative Steroide, Allergen-Immuntherapien und Biologika – sowie der Behandlung von Komorbiditäten wie allergischer Rhinitis oder chronischer Rhinosinusitis.

Schlüsselwörter

Asthma - DMAADs - Rhinitis - chronische Rhinosinusitis - Remission

Keywords

asthma - DMAADs - rhinitis - chronic rhinosinusitis - remission

Publication History

Article published online:
11 June 2024

• Literatur

• 1 Lommatzsch M, Brusselle GG, Canonica GW. et al. Disease-modifying anti-asthmatic drugs. Lancet 2022; 399: 1664-1668 DOI: 10.1016/S0140-6736(22)00331-2. (PMID: 35461560)
• 2 Lommatzsch M. Asthma therapy concepts through the ages. Allergol Select 2024; 8: 1-5 DOI: 10.5414/ALX02445E. (PMID: 38249818)
• 3 Lommatzsch M, Brusselle GG, Levy ML. et al. A(2)BCD: a concise guide for asthma management. Lancet Respir Med 2023; 11: 573-576 DOI: 10.1016/S2213-2600(22)00490-8. (PMID: 36716752)
• 4 Nationale Versorgungsleitlinie (NVL) Asthma, 4. Auflage. 2020 Accessed April 25, 2024 at: https://www.leitlinien.de/themen/asthma/4-auflage
• 5 Lommatzsch M, Criée CP, de Jong CCM. et al. Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 – published by the German Respiratory Society (DGP) e. V. Pneumologie 2023; 77: 461-543 DOI: 10.1055/a-2070-2135. (PMID: 37406667)
• 6 Lommatzsch M. Diagnostik und Therapie von Asthma bei Erwachsenen. Der Pneumologe 2022; 19: 111-121
• 7 Lommatzsch M, Mohme SN, Stoll P. et al. Response to various biologics in patients with both asthma and chronic obstructive pulmonary disease. Respiration 2023; 102: 986-990
• 8 Kraft M, Brusselle G, FitzGerald JM. et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. Eur Respir J 2021; 58: 2100413 DOI: 10.1183/13993003.00413-2021. (PMID: 34112734)
• 9 Couillard S, Laugerud A, Jabeen M. et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 2022; 77: 199-202 DOI: 10.1136/thoraxjnl-2021-217325. (PMID: 34362839)
• 10 Lommatzsch M, Nair P, Virchow JC. Normal blood eosinophil counts in humans. Respiration 2024; 103: 214-216 DOI: 10.1159/000537833. (PMID: 38354723)
• 11 Lommatzsch M. Remission in asthma. Curr Opin Pulm Med 2024; 30: 325-329 DOI: 10.1016/j.jaip.2023.05.047. (PMID: 37301433)
• 12 Lommatzsch M, Buhl R, Canonica GW. et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med 2024; 12: 96-99 DOI: 10.1016/S2213-2600(23)00415-0. (PMID: 38071999)
• 13 Lommatzsch M, Rovas G, Nastev A. et al. Update on asthma 2024 – what the ENT specialist needs to know. Laryngorhinootologie 2024; 103: 219-230
• 14 Fokkens WJ, De Corso E, Backer V. et al. EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology 2024; DOI: 10.4193/Rhin23.415.. (PMID: 38217529)
• 15 White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med 2018; 379: 1060-1070 DOI: 10.1056/NEJMra1712125. (PMID: 30207919)
• 16 Virchow JC, Pfaar O, Lommatzsch M. Allergen immunotherapy for allergic asthma. Allergol Select 2024; 8: 6-11 DOI: 10.5414/ALX02451E. (PMID: 38249819)
• 17 Virchow J, Backer V, Kuna P. et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA 2016; 315: 1715-1725
• 18 Milger K, Suhling H, Skowasch D. et al. Response to biologics and clinical remission in the Adult German Asthma Net Severe Asthma Registry Cohort. J Allergy Clin Immunol Pract 2023; 11: 2701-2712.e2
• 19 Jackson DJ, Heaney LG, Humbert M. et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet 2024; 403: 271-281
• 20 Lommatzsch M, Suhling H, Korn S. et al. Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations. Allergy 2022; 77: 2839-2843 DOI: 10.1111/all.15379. (PMID: 35585763)